Abcg2/Bcrp1 Mediates the Polarized Transport of Antiretroviral Nucleosides Abacavir and Zidovudine
暂无分享,去创建一个
[1] O. Bagasra,et al. Cellular reservoirs of HIV‐1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry , 1996, AIDS.
[2] M. J. van de Vijver,et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.
[3] R. Polk,et al. Pharmacokinetics of [14C]Abacavir, a Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitor, Administered in a Single Oral Dose to HIV-1-Infected Adults: a Mass Balance Study , 1999, Antimicrobial Agents and Chemotherapy.
[4] R. Pomerantz,et al. Twenty years of therapy for HIV-1 infection , 2003, Nature Medicine.
[5] G. Folkers,et al. Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. , 2002, Molecular endocrinology.
[6] Masahiko Watanabe,et al. Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte‐derived soluble factor(s) , 2004, Journal of neurochemistry.
[7] Kelly H. Jordan,et al. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. , 2003, Journal of pharmaceutical sciences.
[8] L. Doyle,et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[9] Y. Sugiyama,et al. In vivo evidence for carrier-mediated efflux transport of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. , 1997, The Journal of pharmacology and experimental therapeutics.
[10] A. Pardee. Role Reversal for Anticancer Agents , 2002, Cancer biology & therapy.
[11] J. Schellens,et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.
[12] S. A. Thomas,et al. Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid. , 2001, The Journal of pharmacology and experimental therapeutics.
[13] Yaron Werber. HIV drug market , 2003, Nature reviews. Drug discovery.
[14] C. Ezzell. AZT given the green light for clinical treatment of AIDS , 1987, Nature.
[15] J. Schellens,et al. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2) , 2005, Cancer Chemotherapy and Pharmacology.
[16] Xin Wang,et al. Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. , 2004, Biochemical pharmacology.
[17] A. Karim. The pharmacokinetics of Norpace. , 1975, Angiology.
[18] S. A. Thomas,et al. The distribution of the anti‐HIV drug, 2′3′‐dideoxycytidine (ddC), across the blood–brain and blood–cerebrospinal fluid barriers and the influence of organic anion transport inhibitors , 2002, Journal of neurochemistry.
[19] J. Yamashita,et al. Expression of Multidrug Resistance-associated Protein (MRP) in Human Gliomas , 2000, Journal of Neuro-Oncology.
[20] D. Dickson,et al. Human immunodeficiency virus-1 infection of the nervous system: an autopsy study of 268 adult, pediatric, and fetal brains. , 1991, Human pathology.
[21] H. Kessler,et al. Therapeutic Drug Monitoring of the HIV/AIDS Drugs Abacavir, Zidovudine, Efavirenz, Nevirapine, Indinavir, Lopinavir, and Nelfinavir , 2003, Pharmacology.
[22] N. Shaik,et al. Drug efflux transporters in the CNS. , 2003, Advanced drug delivery reviews.
[23] H. McClure,et al. Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys , 1991, Antimicrobial Agents and Chemotherapy.
[24] M. Melamed,et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[25] D. Dormont,et al. Atp Binding Cassette Multidrug Transporters Limit the Anti-HIV Activity of Zidovudine and Indinavir in Infected Human Macrophages , 2003, Antiviral therapy.
[26] L. Boone,et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity , 1997, Antimicrobial agents and chemotherapy.
[27] J. Schellens,et al. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. , 2000, Cancer research.
[28] R. Robey,et al. Flow cytometric analysis of breast cancer resistance protein expression and function. , 2002, Cytometry.
[29] J. Schellens,et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.
[30] R. Sawchuk,et al. Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. , 1999, Advanced drug delivery reviews.
[31] E. De Clercq,et al. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites , 2005, Xenobiotica; the fate of foreign compounds in biological systems.
[32] P. Sinko,et al. P-Glycoprotein and Mutlidrug Resistance-Associated Proteins Limit the Brain Uptake of Saquinavir in Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.
[33] S. Wong,et al. Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit: investigation of the inhibitory effect of probenecid utilizing microdialysis. , 1993, The Journal of pharmacology and experimental therapeutics.
[34] Yi Zhang,et al. HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) , 2004, Journal of Pharmacology and Experimental Therapeutics.
[35] M. Barrand,et al. Localisation of breast cancer resistance protein in microvessel endothelium of human brain , 2002, Neuroreport.
[36] E. Wang,et al. Cooperativity in the inhibition of P-glycoprotein-mediated daunorubicin transport: evidence for half-of-the-sites reactivity. , 2000, Archives of biochemistry and biophysics.
[37] F. Clavel,et al. Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir. , 1997, AIDS.
[38] R. Sawchuk,et al. Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. , 1997, Journal of pharmaceutical sciences.
[39] Xin Wang,et al. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. , 2003, Molecular pharmacology.